Every material Form 8-K Savara Inc has filed with the SEC since January 27, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Savara's stockholders approved an increase in authorized common stock from 300,000,000 to 600,000,000 shares and an 18,900,000-share increase to the 2024 Omnibus Incentive Plan at the June 4, 2026 annual meeting. The company also said Chief Financial and Administrative Officer David Lowrance will resign effective July 15, 2026, for health reasons, and that Chief Operating Officer Robert Lutz will become Chief Financial and Operating Officer on that date.
Authorized common shares rise from 300,000,000 to 600,000,000, effective on filing with Delaware on June 4, 2026
Robert Lutz, COO since February 2023, takes the Chief Financial and Operating Officer role effective July 15, 2026, with a $510,000 annual base salary
David Lowrance resigns effective July 15, 2026, due to health reasons, and is expected to enter a consulting agreement at $200 per hour
The 2024 Plan increase of 18,900,000 shares passed with 156,664,451 votes for and 2,324,514 against
Savara Inc. signed a lease on March 10, 2026 for about 10,795 square feet of office space in Yardley, Pennsylvania, where it plans to move its headquarters. The lease term starts July 1, 2026 and runs to December 1, 2031. The filing describes a routine facilities agreement with no financial results, guidance, or capital raise included.
Lease covers about 10,795 square feet at 19 W. College Avenue, Suite 200, Yardley, PA, with landlord ML7 Yardley Partners, LP
Term runs July 1, 2026 to December 1, 2031, with an option to extend five years
Monthly base rent of about $28,337 in year one, rising about 2% annually; aggregate base rent about $1.78 million after five months of abatement
Company has paid a security deposit equal to $28,337
Savara amended its March 2025 Loan and Security Agreement with Hercules Capital and its lenders on January 26, 2026. The loan allows borrowing of up to $105 million in term loans, with up to $75 million of additional draws now conditioned on FDA approval of MOLBREEVI for aPAP, and two financial covenant compliance dates were extended.
Total borrowing capacity under the Loan Agreement is up to $105 million in term loans.
Up to $75 million of additional draws become available after FDA approval of MOLBREEVI for aPAP: $45 million first, then $30 million.
Draw windows end on the earlier of 120 days after approval or June 30, 2027.
Unrestricted cash covenant compliance extended to April 1, 2027; minimum trailing six-month revenue covenant extended to September 30, 2027, if market capitalization falls below set thresholds.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Savara Inc filing is on SEC EDGAR ↗. 8-K briefs of other companies →